Get the Stockscreener App
4.3299
1.48%
-0.0601
Codexis Inc stock is traded at $4.3299, with a volume of 252.39K.
It is down -1.48% in the last 24 hours and down -13.33% over the past month.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
See More
Previous Close:
$4.39
Open:
$4.4
24h Volume:
252.39K
Relative Volume:
0.35
Market Cap:
$357.25M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-3.9008
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
+3.22%
1M Performance:
-13.33%
6M Performance:
+43.21%
1Y Performance:
+55.58%
1-Day Range:
$4.28
$4.505
1-Week Range:
$4.00
$4.51
52-Week Range:
$2.56
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
4.325 | 357.25M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.61 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
650.90 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.54 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Codexis strengthens board with biotech veteran Arthur Levin By Investing.com - Investing.com Nigeria
Codexis strengthens board with biotech veteran Arthur Levin - Investing.com India
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - GlobeNewswire
Codexis, Inc. Appoints Arthur Levin to Strategic Advisory Board -February 06, 2025 at 04:05 pm EST - Marketscreener.com
Codexis (NASDAQ:CDXS) investors are sitting on a loss of 79% if they invested three years ago - Yahoo Finance
Taking a Closer Look At Codexis Inc (CDXS) Following Its Recent Trade - Knox Daily
Can you now get a good deal on Codexis Inc’s shares? - US Post News
Biocatalysis Market is Projected to Increase at a CAGR of 5.2% - openPR
Ratio Revelations: Codexis Inc (CDXS)’s Financial Metrics in the Spotlight - The Dwinnex
Codexis, Inc. (NASDAQ:CDXS) Short Interest Update - MarketBeat
Institutional investors in Codexis, Inc. (NASDAQ:CDXS) see US$59m decrease in market cap last week, although long-term gains have benefitted them. - Simply Wall St
Inspire Investing LLC Takes $405,000 Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Has $1.37 Million Stock Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Cantor Fitzgerald Forecasts Codexis FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on Codexis FY2025 Earnings - MarketBeat
Codexis expands board with new director Christos Richards - MSN
Codexis, Inc. (NASDAQ:CDXS) Sees Significant Increase in Short Interest - MarketBeat
Codexis expands board with new director Christos Richards By Investing.com - Investing.com Australia
Tallon Kerry Patrick Purchases New Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Barclays PLC Purchases 70,255 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Barclays PLC Has $640,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis appoints new independent director By Investing.com - Investing.com Australia
Codexis, Inc. Appoints Christos Richards to Board of Directors -January 16, 2025 at 04:05 pm EST - Marketscreener.com
Codexis appoints new independent director - Investing.com India
Codexis Appoints Christos Richards to Board of Directors - TipRanks
Codexis Strengthens Board with Life Sciences Veteran Christos Richards, Expert in 450+ Executive Placements - StockTitan
Jane Street Group LLC Reduces Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Synthetic DNA Market Set to Witness Stunning Growth by 2024 Ti - openPR
Codexis Announces New Employment Inducement Grants - The Manila Times
Codexis Awards Strategic Equity Grants to New Employees Under 2024 Inducement Plan - StockTitan
Is There An Opportunity With Codexis, Inc.'s (NASDAQ:CDXS) 22% Undervaluation? - Yahoo Finance
Codexis sees $210,994 stock purchase by Opaleye management - Investing.com Nigeria
Estimating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS) - Simply Wall St
Geode Capital Management LLC Boosts Stake in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Caribou Biosciences Strengthens Leadership Team with Veteran Biotech CFO Sri Ryali - StockTitan
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Codexis, Inc. (NASDAQ:CDXS) Short Interest Up 10.5% in December - MarketBeat
State Street Corp Acquires 41,480 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Stifel Financial Corp Lowers Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Stifel Financial Corp Has $530,000 Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
BNP Paribas Financial Markets Trims Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution - Investing.com India
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution By Investing.com - Investing.com South Africa
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Codexis Inc Stock (CDXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jan 30 '25 |
Buy |
4.49 |
20,000 |
89,782 |
8,610,000 |
| Opaleye Management Inc. | 10% Owner |
Dec 30 '24 |
Buy |
4.70 |
35,000 |
164,392 |
8,580,000 |
| Opaleye Management Inc. | 10% Owner |
Dec 31 '24 |
Buy |
4.66 |
10,000 |
46,603 |
8,590,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 25 '24 |
Buy |
2.91 |
25,000 |
72,720 |
8,545,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 24 '24 |
Buy |
2.94 |
80,000 |
234,856 |
8,515,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 25 '24 |
Buy |
2.86 |
5,000 |
14,290 |
8,520,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 20 '24 |
Buy |
3.01 |
1,055,000 |
3,175,550 |
8,390,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 23 '24 |
Buy |
2.94 |
45,000 |
132,484 |
8,435,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 18 '24 |
Buy |
3.16 |
61,000 |
192,992 |
7,380,000 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):